GlassScriptPhysician profile
Jose V Sibal
NPI 1912903758
$5,605.29
in general payments reported to CMS, 2019-2025
26 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,083 · 2020: $692 · 2021: $1,415 · 2022: $957 · 2023: $435 · 2024: $755 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441 · Education: $16.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.36 |
| Education | $16.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,128.70 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $613.66 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $561.37 | 2020-2024 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $532.96 | 2019-2022 | |
| Akebia Therapeutics INC | $415.37 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $394.56 | 2019-2024 | Velphoro |
| Aurinia Pharma U.S., INC. | $357.95 | 2021-2023 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $273.71 | 2019-2021 | |
| Daiichi Sankyo INC. | $268.70 | 2019-2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $238.84 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.18 | 2021 | |
| Opko Pharmaceuticals, LLC | $97.76 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $93.13 | 2019 | |
| Amgen INC. | $65.25 | 2024-2025 | Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.43 | 2022-2024 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $58.31 | 2024 | Ibsrela |
| Travere Therapeutics, INC. | $45.59 | 2022-2023 | |
| Horizon Therapeutics Plc | $40.26 | 2019 | |
| Calliditas Therapeutics US INC. | $35.45 | 2022-2023 | Tarpeyo |
| Glaxosmithkline, LLC. | $30.45 | 2022 | |
| Kyowa Kirin, INC. | $27.84 | 2024 | Crysvita |
| Janssen Pharmaceuticals, INC | $26.18 | 2019 | |
| Amarin Pharma, INC. | $23.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.04 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.39 | 2019 | |
| Merck Sharp & Dohme LLC | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Sibal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.